Cel­gene forges can­cer pact with CRT; FDA OKs Pfiz­er's Xel­janz as treat­ment for pso­ri­at­ic arthri­tis

→ Cel­gene has signed a five-year deal with Can­cer Re­search UK’s sub­sidiary Can­cer Re­search Tech­nol­o­gy to dis­cov­er, de­vel­op, and com­mer­cial­ize on­col­o­gy drugs. The duo will work on mR­NA trans­la­tion, the cel­lu­lar process of as­sem­bling pro­teins. Mul­ti­ple onco­genes and tu­mor sup­pres­sors act on trans­la­tion ma­chin­ery, and dys­reg­u­la­tion of pro­tein syn­the­sis is a com­mon fea­ture of can­cer cells. Tar­get­ing the process could dis­rupt the spread of can­cer. Un­der the agree­ment, Cel­gene is pay­ing an undis­closed up­front fee to Can­cer Re­search Tech­nol­o­gy. In re­turn, the phar­ma gi­ant gets the op­tion to buy US rights to projects that arise from the col­lab­o­ra­tion, and ac­cess to glob­al rights at the end of Phase I tri­als. Can­cer Re­search Tech­nol­o­gy is el­i­gi­ble for roy­al­ties and mile­stones. “This is our largest drug dis­cov­ery col­lab­o­ra­tion to date and rep­re­sents a ma­jor en­dorse­ment of the rep­u­ta­tion and scale of our ca­pac­i­ty and ex­per­tise in both drug dis­cov­ery and clin­i­cal de­vel­op­ment by a lead­ing in­dus­try part­ner,” said Iain Foulkes, Can­cer Re­search Tech­nol­o­gy’s CEO, in a state­ment.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.